{"filing":{"accession_number":"0001193125-26-347196","cik":"0001479615","ticker":"SLNCF","company_name":"Silence Therapeutics plc","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-10","primary_document":"d168365d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526347196/d168365d8k.htm"},"events":[{"id":27368,"run_id":24936,"accession_number":"0001193125-26-347196","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Silence Therapeutics entered into an underwriting agreement on August 11, 2026 to issue and sell approximately 12.96 million ADSs at $13.50 per ADS, generating approximately $164.0 million in net proceeds (or $188.7 million if the underwriters' 30-day option to purchase up to 1.94 million additional ADSs is fully exercised). This registered public offering will dilute existing shareholders and materially affect the company's capital structure.","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28876,"accession_number":"0001193125-26-347196","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Silence Therapeutics entered into an underwriting agreement on August 11, 2026 to issue and sell 12,962,963 ADSs (each representing three ordinary shares) at $13.50 per ADS, with an additional 30-day option for underwriters to purchase up to 1,944,444 ADSs. The offering is expected to generate approximately $164.0 million in net proceeds (or $188.7 million if the option is fully exercised). This is a registered public offering of equity securities that will dilute existing shareholders and materially affect the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T21:24:44.772371+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28877,"accession_number":"0001193125-26-347196","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silence Therapeutics announced and priced an underwritten public offering of approximately $175 million in American Depositary Shares (ADSs) at $13.50 per ADS, with an additional 30-day option for underwriters to purchase up to 15% more. This is a registered public offering of equity securities that will dilute existing shareholders. The exhibits confirm commencement on August 10 and pricing on August 11, 2026, with expected closing on August 13, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T21:24:44.772371+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28876,"accession_number":"0001193125-26-347196","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Silence Therapeutics entered into an underwriting agreement on August 11, 2026 to issue and sell 12,962,963 ADSs (each representing three ordinary shares) at $13.50 per ADS, with an additional 30-day option for underwriters to purchase up to 1,944,444 ADSs. The offering is expected to generate approximately $164.0 million in net proceeds (or $188.7 million if the option is fully exercised). This is a registered public offering of equity securities that will dilute existing shareholders and materially affect the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T21:24:44.772371+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-12"},{"id":28877,"accession_number":"0001193125-26-347196","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Silence Therapeutics announced and priced an underwritten public offering of approximately $175 million in American Depositary Shares (ADSs) at $13.50 per ADS, with an additional 30-day option for underwriters to purchase up to 15% more. This is a registered public offering of equity securities that will dilute existing shareholders. The exhibits confirm commencement on August 10 and pricing on August 11, 2026, with expected closing on August 13, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T21:24:44.772371+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-12"}]}